Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial
L. Bjermer (Lund, Sweden), C. Vogelmeier (Marburg, Germany), E. Kerwin (Medford, OR, United States of America), I. Boucot (Brentford, Middlesex, United Kingdom), F. Maltais (Québec, QC, Canada), L. Tombs (Brentford, Middlesex, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), P. Jones (Brentford, Middlesex, United Kingdom)
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Bjermer (Lund, Sweden), C. Vogelmeier (Marburg, Germany), E. Kerwin (Medford, OR, United States of America), I. Boucot (Brentford, Middlesex, United Kingdom), F. Maltais (Québec, QC, Canada), L. Tombs (Brentford, Middlesex, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), P. Jones (Brentford, Middlesex, United Kingdom). Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial. 797
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: